Kritische 8-K Meldungen
HOCH Abgang Schlüsselpersonen (09.03.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 09.03.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | n furnished or incorporated by reference therein. Item 5.02 Departure of Directors or Certain Officers; Election of Dire |
| 12.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 15.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 20.08.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
Stammdaten
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
Unternehmen & Branche
| Name | Boundless Bio, Inc. |
|---|---|
| Ticker | BOLD |
| CIK | 0001782303 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 32,3 Mio. USD |
| Beta | -0,26 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -58,197,000 | -2.60 | 157,059,000 | 98,654,000 | |
| 2025-09-30 | 10-Q | -13,879,000 | -0.62 | 168,721,000 | 110,169,000 | |
| 2025-06-30 | 10-Q | -15,675,000 | -0.70 | 179,453,000 | 122,691,000 | |
| 2025-03-31 | 10-Q | -15,758,000 | -0.71 | 191,242,000 | 136,592,000 | |
| 2024-12-31 | 10-K | -65,363,000 | -3.85 | 206,409,000 | 150,642,000 | |
| 2024-09-30 | 10-Q | -16,509,000 | -0.74 | 175,093,000 | 165,083,000 | |
| 2024-06-30 | 10-Q | -16,976,000 | -0.77 | 188,203,000 | 179,246,000 | |
| 2024-03-31 | 10-Q | -15,430,000 | -12.27 | 117,077,000 | -141,184,000 | |
| 2023-12-31 | 10-K | -49,434,000 | -40.65 | 129,894,000 | -127,082,000 | |
| 2023-09-30 | 10-Q | -13,173,000 | -10.71 | |||
| 2023-06-30 | 10-Q | -12,398,000 | -10.28 | |||
| 2023-03-31 | 10-Q | -11,719,000 | -9.91 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.